PubMed Journals Articles About "Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom" RSS

15:47 EST 18th January 2019 | BioPortfolio

Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom articles that have been published worldwide.

More Information about "Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom" on BioPortfolio

We have published hundreds of Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom news stories on BioPortfolio along with dozens of Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom Clinical Trials and PubMed Articles about Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom Companies in our database. You can also find out about relevant Post-Authorization Safety Study Of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) In The United Kingdom Drugs and Medications on this site too.

Showing "Post Authorization Safety Study Biologicals Pandemic Influenza Vaccine" PubMed Articles 1–25 of 68,000+

Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

As part of the U.S. Department of Health and Human Services (HHS) Pandemic Influenza Plan preparedness and response strategy, the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program was established by the Biomedical Advanced Research and Development Authority (BARDA) in 2005 with the goal of building and maintaining a stockpile of vaccines for influenza viruses with pandemic potential to vaccinate 20 million people in the critical workforce in the event of a pandemic. The NPIVS program continu...

Value of inventory information in allocating a limited supply of influenza vaccine during a pandemic.

To understand the value of information on vaccine inventory levels during an influenza pandemic, we propose a simulation study to compare vaccine allocation strategies using: (i) only population information (pro-rata, or population-based, PB), (ii) both population and vaccine inventory information (population and inventory-based, PIB).

Pandemic influenza vaccines: what they have taught us about B cell immunology.

The emergence of avian influenza viruses stimulated pandemic concerns and efforts to develop protective vaccines. Studies of the immune responses to experimental vaccines for pandemic influenza have taught us lessons about human immunity to influenza in general that can be applied to seasonal, pandemic, and even universal vaccine responses. For example, the concepts of targeting the hemagglutinin stalk and elicitation of stalk reactive antibodies grew out of studies of the 2009 pandemic H1N1 vaccines. More ...

The long-run effects of pandemic influenza on the development of children from elite backgrounds: Evidence from industrializing Japan.

This study estimates the lingering effects of fetal exposure to the 1918 influenza pandemic on the development of secondary school and girls' high school students in industrializing Japan. In order to refine the verification of the fetal origins hypothesis, we tried not only to focus on children from elite schools but also to construct the continuous influenza mortality measure using monthly variations in the number of births and influenza deaths. By utilizing a nationwide multidimensional physical examinat...

Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study.

Vaccine safety signals require investigation, which may be done rapidly at the population level using ecological studies, before embarking on hypothesis-testing studies. Incidence rates were used to assess a signal of narcolepsy following AS03-adjuvanted monovalent pandemic H1N1 (pH1N1) influenza vaccination among children and adolescents in Sweden and Finland in 2010. We explored the utility of ecological data to assess incidence of narcolepsy following exposure to pandemic H1N1 virus or vaccination in 10 ...

Low coverage rate and awareness of influenza vaccine among older people in Shanghai, China: a cross-sectional study.

Older individuals are at high risk for morbidity and mortality due to influenza, and the most effective way to prevent influenza is yearly vaccination. In China, the influenza vaccine is not covered by the national Expanded Program on Immunization, and more evidence is needed about influenza vaccine usage among older individuals.

Significance of the detection of Influenza and other respiratory viruses for Antibiotic Stewardship: The lessons from post-pandemic period.

We aimed to describe the factors associated with antibiotic use in upper respiratory tract infections (URTI) in post-pandemic influenza period.

Timely Antiviral Administration During an Influenza Pandemic: Key Components.

Prompt treatment of ill persons with influenza antivirals will be an important part of a future pandemic influenza response. This essay reviews key lessons learned from the 2009 H1N1 pandemic and the changing landscape of antiviral drug availability, and identifies and describes the multiple components needed to ensure the timely administration of antiviral drugs during a future pandemic. Fortunately, many of these planning efforts can take place before a pandemic strikes to improve outcomes during a future...

Redefining influenza seasonality at a global scale and aligning it to the influenza vaccine manufacturing cycle: a descriptive time series analysis.

Annual seasonal influenza vaccine manufacturing cycles align with temperate country seasonality in each hemisphere, yet influenza seasonality is poorly defined for many countries. The study introduces a novel and universal approach to defining and classifying seasonality that can be used to classify any country's influenza vaccine cycle alignment.

A neuraminidase activity-based microneutralization assay for evaluating antibody responses to influenza H5 and H7 vaccines.

Outbreaks of the highly pathogenic avian influenza H5N1 and H7N9 viruses have spurred an unprecedented research effort to develop antivirals and vaccines against influenza. Standardized methods for vaccine evaluation are critical for facilitating vaccine development. Compared with hemagglutination inhibition assays, mounting evidence suggest that microneutralization tests (MNTs) is a better choice for the evaluation of candidate pandemic influenza vaccines because they measure neutralizing antibody activity...

Evaluation of the field-protective effectiveness of seasonal influenza vaccine among Korean children aged < 5 years during the 2014-2015 and 2015-2016 influenza seasons: a cohort study.

A field effectiveness evaluation of the influenza vaccine among children younger than five years is important due to the high burden of influenza in this age group. The epidemiology of influenza virus changes rapidly each year. Moreover, the development of a new type of influenza vaccine is accelerating, necessitating a new field effectiveness evaluation.

A Live-Attenuated Prime, Inactivated Boost Vaccination Strategy with Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccines Provides Protection in Ferrets: A Confirmatory Study.

Influenza viruses cause severe diseases and mortality in humans on an annual basis. The current influenza virus vaccines can confer protection when they are well-matched with the circulating strains. However, due to constant changes of the virus surface glycoproteins, the vaccine efficacy can drop substantially in some seasons. In addition, the current seasonal influenza virus vaccines do not protect from avian influenza viruses of human pandemic potential. Novel influenza virus vaccines that aim to elicit ...

100 years since the 1918 influenza pandemic-progress made, yet questions remain. A synopsis of the 4th New Zealand Influenza Symposium, February 2018.

The year 2018 marks 100 years since the 1918 influenza pandemic that caused devastating social and economic destruction worldwide. Despite substantial progress made with influenza research and strategies to control disease outbreaks, influenza continues to be a global public health problem. This paper presents a synopsis of the 4th New Zealand Influenza Symposium hosted by the Immunisation Advisory Centre in February 2018. During this symposium, international and national experts and service providers conve...

The Pandemic Influenza 1918.

The pandemic influenza 1918 was the greatest pandemic of the 20th century with a high death toll worldwide. Due to the wartime, the public reaction in Germany to the pandemic was subdued. The international scientific debate in Europe began with the first publications by the Deutsche Medizinische Wochenschrift in July 1918. One of the many open questions was the search for the infectious agent causing influenza which was not solved until 1930. The historical publications and additional later research clearly...

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

Children are susceptible to severe influenza infections and facilitate community transmission. One potential strategy to improve vaccine immunogenicity in children against seasonal influenza involves a trivalent hemagglutinin DNA prime-trivalent inactivated influenza vaccine (IIV3) boost regimen.

Broadly protective influenza vaccines: design and production platforms.

Effective vaccines are the cornerstone of our defenses against acute influenza virus infections that result in ∼500 000 annual deaths worldwide. For decades, an on-going concerted effort has been to develop a universal influenza vaccine to combat the looming threat of potentially pandemic emerging and re-emerging influenza viruses. To address the need for rapid efficacious vaccines that could mitigate the impact of seasonal and future pandemics, multiple platforms are under development and/or investigat...

Influenza vaccine failure: Failure to protect or failure to understand?

I propose that influenza vaccine failure be defined as receipt of a properly stored and administered vaccine with the subsequent development of documented influenza. Several mechanisms of vaccine failure occur and can-sometimes in combination-lead to what is termed "vaccine failure." Influenza vaccine failure occurs for a variety of reasons, many of which are not true failures of the vaccine (e.g., improper vaccine storage and handling). Areas covered: In this article, I discuss common causes of "vaccine fa...

Pandemic influenza and subsequent risk of type 1 diabetes: a nationwide cohort study.

Case reports have linked influenza infections to the development of type 1 diabetes. We investigated whether pandemic and seasonal influenza infections were associated with subsequent increased risk of type 1 diabetes.

Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.

Influenza infection could be more effectively controlled if a multi-purpose vaccine with the ability to induce responses against most, or all, influenza A subtypes could be generated. Conserved viral proteins are a promising basis for the creation of a broadly protective vaccine. In the present study, the immunogenicity and protective properties of three recombinant proteins (vaccine candidates), comprising conserved viral proteins fused with bacterial flagellin, were compared.

Evidence of pandemic H1N1 influenza exposure in dogs and cats, Thailand: A serological survey.

Influenza A virus causes respiratory disease in both humans and animals. In this study, a survey of influenza A antibodies in domestic dogs and cats was conducted in 47 animal shelters in 19 provinces of Thailand from September 2011 to September 2014. One thousand and eleven serum samples were collected from 932 dogs and 79 cats. Serum samples were tested for influenza A antibodies using a multi-species competitive NP-ELISA and haemagglutination inhibition (HI) assay. The NP-ELISA results showed that 0.97% ...

Historical and clinical aspects of the 1918 H1N1 pandemic in the United States.

One hundred years have passed since the 1918 influenza pandemic caused substantial illness globally, with an estimated 50 million deaths. A number of factors, including World War I, contributed to the spread of the pandemic virus, which often caused high symptomatic attack rates and severe illness. Major achievements over the last 100 years have been made in influenza prevention, diagnosis, and treatment; however, the potential for a severe pandemic to emerge remains unchanged. We provide a review of the hi...

Seasonal influenza vaccine effectiveness at primary care level, Hong Kong SAR, 2017/2018 winter.

The 2017/18 winter influenza season in Hong Kong SAR started in early January 2018, predominated by influenza B/Yamagata. We collaborated with private medical practitioners of our sentinel surveillance system to collect respiratory specimens and clinical information from patients with influenza-like illness for estimation of the influenza vaccine effectiveness (VE) using the test-negative case-control design. We found that the overall VE was 59.1% (95%CI 41.1 to 71.8%) against all influenza and 53.5% (95%CI...

Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine.

During the height of the 2009 H1N1 swine-derived influenza pandemic, a clinical trial was conducted in which seven subjects were immunized using a monovalent, MF59®-adjuvanted vaccine, developed from an egg-passaged candidate vaccine virus (CVV), A/California/07/2009 X-181. Whole blood was collected prior to immunization and at 8, 22, and 202 days post-vaccination, and subjects' serological responses were evaluated. Here, we reconstruct and examine the longitudinal, influenza-specific circulating B cell ...

Registry Cohort Study to Determine Risk for Multiple Sclerosis after Vaccination for Pandemic Influenza A(H1N1) with Arepanrix, Manitoba, Canada.

To investigate a potential risk for multiple sclerosis (MS) after vaccination with Arepanrix, the GlaxoSmithKline AS03-adjuvanted influenza A(H1N1)pdm09 vaccine, we used the provincewide immunization registry for Manitoba, Canada, to match 341,347 persons vaccinated during the 2009 pandemic to 485,941 unvaccinated persons on age, sex, address, and a propensity score measuring the probability of vaccination. We used a previously validated algorithm to identify MS cases from provincial hospital, physician, an...

Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Despite the widespread use of seasonal influenza vaccines, there is urgent need for a universal influenza vaccine to provide broad, long-term protection. A number of factors underpin this urgency, including threats posed by zoonotic and pandemic influenza A viruses, suboptimal effectiveness of seasonal influenza vaccines, and concerns surrounding the effects of annual vaccination. In this article, we discuss approaches that are being investigated to increase influenza vaccine breadth, which are near-term, r...

Quick Search